The anti-proliferative activity of MK-2206, an AKT inhibitor, in multiple human cancer cell lines—and the evidence of human toleration and AKT inhibition—led the way towards investigation in patients with PIK3CA-mutant ER-positive and HER2-negative breast cancers in neoadjuvant settings for individualized treatment options. This evidence concerns the gene PIK3CA and breast cancer.